Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3. Selvaggi, G., Wu, Y., Wang, Z., Wu, G., Poddubskaya, E., Reck, M., Mok, T., Chiappori, A., Lee, D. H., Breder, V., Orlov, S., Cicin, I., Cheng, Y., Liu, Y., Fan, Y., Zhou, J., Liang, C., Mao, L., Horn, L., Wakelee, H. A. ELSEVIER SCIENCE INC. 2021: S232–S233
View details for Web of Science ID 000631349600306